This message was sent to ##Email##
|
|
|
|
|
| |
| HEALTH CARE NEWS AND UPDATES |
Berkeley News
Over the course of her lifetime, a woman has a one in eight chance of developing breast cancer. The earlier the cancer is detected, the more likely bad luck can turn to good.
Now new technology being developed by UC Berkeley engineers could dramatically improve the speed and accuracy of early breast cancer detection through the use of microfluidics.
READ MORE
TIME
After Keith Beck died of bile duct cancer last year, family members said, more than 900 people showed up to pay respects to the popular athletic director at the University of Findlay in northwestern Ohio.
Many were former students who recalled acts of kindness during Beck’s nearly 30-year career: $20 given to a kid who was broke, textbooks bought for a student whose parents were going through bankruptcy, a spot cleared to sleep on Beck’s living room floor. But few knew about Beck’s final gesture of generosity. The 59-year-old had agreed to a “rapid autopsy,” a procedure conducted within hours of his death on March 28, 2017, so that scientists could learn as much as possible from the cancer that killed him.
READ MORE
|
Promoted by
|
|
|
|
 |
WebMD
A cancer scare could increase the chances that you'll be diligent about recommended screenings in the future, a new study finds.
People who got a false-positive result on a breast or prostate cancer screening test were more likely to adhere to screening guidelines for breast cancer and colon cancer going forward, researchers found.
READ MORE
The New York Times
About two-thirds of smokers will die early from cigarette-based illnesses. Cigarettes are also very addictive. Because of this, it seems reasonable to place warnings on their labels.
If a Los Angeles Superior Court judge has his way, California businesses will have to put similar warnings on something else that can be addictive, coffee. His ruling, which is being challenged by coffee producers, is harder to justify in terms of health — if it can be justified at all.
READ MORE
 |
|
Our ihcDirect® method yields a revolutionary technology that opens a spectrum of new clinical applications including intraoperative surgery. Using the Novodiax PolyHRP technology, Intraoperative IHC tests can now be completed in just 10 minutes using fresh frozen tissues.
For more details, see our ihcDirect® product list.
|
|
Forbes
We in the rich societies of the world don’t hear a lot about aflatoxin. It is probably one of the single largest causes of cancer in the developing world — particularly in Africa. Around a half a billion people are at risk from this toxin in their diet. At high doses it can cause acute poisoning and death in high doses. It also causes cognitive stunting in children exposed to it.
READ MORE
Science Magazine
For people with advanced cancer who are running out of options, many cancer centers now offer this hope: Have your tumor’s genome sequenced, and doctors will match you with a drug that targets its weak spot. But this booming area of cancer treatment has critics, who say its promise has been oversold. Recently, two prominent voices in the field faced off in a sometimes-tense debate on what’s often called precision oncology at the annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois. Their dispute threw a splash of cold water on a meeting packed with sessions on genome-based cancer treatments.
READ MORE
 |
|
Donate now to help Doctors Without Borders bring emergency medical care where it is needed most. Doctors Without Borders USA relies on unrestricted donations from private donors so when an emergency strikes we assess the needs and can act fast. Donate today.
|
|
Medical Xpress
Newcastle and Dundee University researchers have uncovered an alternative path of how the breast cancer drug palbociclib drives malignant cells into cell death, senescence. Palbociclib is a drug used for the treatment of advanced estrogen-receptor-positive breast cancer. It induces cell cycle arrest and senescence, an irreversible resting state marking these "out-of-order" cells to be cleared by the immune system.
READ MORE
ScienceDaily
Researchers tracked genomic alterations detected in patient samples during tumor cell evolution in culture, in patient-derived xenograft (PDX) mouse models from the cultures, as well as before and after treatment in patients. The team reports that tumor progression was often driven by cancer-promoting genes, known as oncogenes, on extrachromosomal pieces of DNA.
READ MORE
|
Promoted by
|
|
|
|
 |
| ACS CANCER PROGRAMS UPDATES |
ACS
Registration is now open for an upcoming live webinar on coding radiation using the new radiation data items. The speakers will discuss why the changes to the radiation codes are necessary, review the codes and coding instructions, work through coding scenarios and have time for Q&A.
Space is limited and pre-registration is required.
Webinar: Coding Radiation 2018
Date: Wednesday, May 16
Time: 11 a.m. Pacific | 12 p.m. Mountain | 1 p.m. Central | 2 p.m. Eastern
Duration: 1 hour
Cost: The webinar is free of charge.
Presenters:
Robin Billet, Georgia Cancer Registry
Jim Hofferkamp, NAACCR
Kathleen Thoburn, National Cancer Database (NCDB)
CE Credit: This presentation has not been approved for CEs.
Presentation System: This live webinar will be hosted through WebEx, and audio is available through your computer or phone.
READ MORE
Cancer Program- NCDB
An update to your CQIP 2017 Annual Report has been released impacting Slide 49 - Number of Major Surgical Resections for Selected Cancers, 2013 - 2015 - My Facility, “Lung Resection” includes all lung cancer resections for major surgeries (Surgical Procedure of Primary Site at This Facility / Codes 30 through 80 / NAACCR Item #670) and Slide 53 - NSCLC Resections, Unadjusted 30, 90 Day Mortality, 95 percent CI, 2013 - 2015 - My Facility vs. All CoC and CoC High Volume, changed to include only Non-Small Cell Lung (NSCLC) cases. Slides that are impacted are denoted as “Updated March 2018.” The remaining CQIP slides remain unchanged.
If you have any questions, please contact ncdbcqip@facs.org.
ACS-CRP
The Commission on Cancer (CoC) initiated a pilot study at 20 CoC-accredited facilities in the fall of 2017 as a component of the Comparison of Operative to Monitoring and Endocrine Therapy (COMET) clinical trial (PIs: Drs. Shelley Hwang, Ann Partridge, Alastair Thompson). The study examines the risks and benefits of active surveillance compared with usual care for patients diagnosed with low risk ductal carcinoma in situ (DCIS), commonly known as stage 0 breast cancer. The pilot study concluded Jan. 1, 2018. Following data analysis, a CoC Special Study will be launched in spring 2018 to investigate outcomes from DCIS treatment retrospectively.
READ MORE
American College of Surgeons - NAPRC
The National Accreditation Program for Rectal Cancer (NAPRC) is now accepting applications. The NAPRC was developed to ensure that rectal cancer patients receive appropriate care following a multidisciplinary approach. Programs will be evaluated on the standards and metrics outlined in The National Accreditation Program for Rectal Cancer Standards Manual 2017 (revised October 2017).
READ MORE
NAPBC
The National Accreditation Program for Breast Centers (NAPBC) has released the 2018 NAPBC Standards Manual.
You can download a PDF of the manual from the NAPBC Standards web page.
Click the 2018 NAPBC Standards Manual link at the top of the standards web page. If your browser is set to auto-download, check the downloads folder on your computer after clicking the link.
The 2018 NAPBC Standards Manual will be available online and as a PDF. The NAPBC will not have printed copies of the manual for purchase.
Please contact us at NAPBC@facs.org with any questions or comments.
READ MORE
| IMPORTANT DATES AND DEADLINES |
| Date |
Event |
Location |
| June 1 |
Call for Data closes
|
|
| July 21-24 |
ACS Quality and Safety Conference
|
Orlando, FL
|
| Sept. 5-7 |
2018 Cancer Programs Conference
|
Chicago, IL
|
| Oct. 21-25 |
ACS Clinical Congress
|
Boston, MA
|
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The Cancer Programs do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the authors and not of the American College of Surgeons, and the Cancer Programs.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
